ArriVent BioPharma published Phase 1b results for firmonertinib, highlighting its potential as the first oral, chemotherapy-free targeted therapy for treatment-naïve patients with advanced EGFR PACC-mutant non-small cell lung cancer (NSCLC). This mutation affects about 12% of EGFR-mutant lung cancers and currently lacks a standard targeted treatment. The drug demonstrated strong clinical activity, including high response rates and progression-free survival, as well as meaningful brain metastasis response. ArriVent is advancing firmonertinib into a global Phase 3 trial to address this significant unmet medical need.
ArriVent's cancer cell publication on firmonertinib comes as the health sector on Pluang shows mixed activity, with 68 of 150 priced US health stocks rising and 54 falling as of Oct 19, 2026, 18:43 WIB. Notable movers include Heron Therapeutics Inc (HRTX) at USD 0.37 with a 2.49% increase, Revolution Medicines Inc. (RVMD) at USD 181.96 up 2.25%, and Arrowhead Pharmaceuticals Inc. (ARWR) at USD 56.94 rising 1.86%. Typical hold times on Pluang vary from 4 to 36 days among these stocks.
Bill Gross, a serial entrepreneur behind over 175 companies, has launched Idealab.ai, a platform using AI to generate and share over 1.2 million business ideas based on real-world problems. The platform aims to lower barriers to entrepreneurship by h...
The Portnoy Law Firm has launched an investigation into Cardinal Infrastructure Group for possible securities fraud following the company's Q2 2026 financial report. Cardinal revealed a decline in its gross profit margin to 10.8%, down from 13.9% the...
AIOS Tech Inc. announced an agreement to acquire SmartCore Holdings Limited in an all-stock transaction valued at approximately $100 million. The deal will issue 33.3 million AIOS shares to SmartCore's sellers, who will hold about 80% of AIOS shares ...
XBiotech announced positive results from the Phase II TASKIN trial, where their antibody vilamakitug combined with standard chemotherapy improved 12-month overall survival to 61.3% in refractory metastatic colorectal cancer patients, surpassing the s...
Proof and Circle Internet Group demonstrated a new system where AI agents can prove the identity of the person they represent using Proof's x401 open identity protocol and pay merchants in USDC via Circle's x402 payment protocol. This innovation addr...
